Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.<；p>；FORMA DE DOSIS ORAL QUE COMPRENDE UNA COMPOSICIÓ；N FARMACÉ；UTICA EN FORMA DE COMPRIMIDO QUE COMPRENDE 65% P/P O 65-95% P/P DE FUMARATO DE DIMETILO Y UNO O MÁ；S EXCIPIENTES； USO PARA TRATAR O MEJORAR ESCLEROSIS MÚ；LTIPLE； MÉ；TODO DE PREPARACIÓ；N.<；/p>；
